SONICURE（SONICracker for the Treatment of UndeRExpansion）

Inclusion Criteria: * Aged between 18 and 80 years old, either male or non - pregnant female. * Suffering from heart diseases with clinical evidence of ischemia, such as Chronic Coronary Syndrome (CCS) or Acute Coronary Syndrome (ACS). * The subject should be able to understand the purpose of the trial, voluntarily participate in it, and sign the informed consent form. * During the baseline surgery, at most one target lesion can be treated. * The target lesion and non - target lesion are not located in the same blood vessel. * The reference vessel diameter of the target lesion is 2.25 - 4.0 mm (estimated visually). Exclusion Criteria: * Patients who have had any myocardial infarction within 1 week, or patients who have had a myocardial infarction more than 1 week ago but whose myocardial enzymes CK or CK-MB have not yet returned to normal. * Patients with New York Heart Association (NYHA) class III or IV heart failure or those with severe valvular heart disease. * Female patients who are planning to become pregnant (or are breastfeeding). * Severe impairment of liver and kidney function, with transaminase levels more than 3 times the upper limit of the normal value, serum creatinine \> 2.5 mg/dL (221 μmol/L), or chronic renal failure requiring long-term dialysis. * Severe hypertension that cannot be controlled despite treatment (systolic blood pressure persistently \> 180 mmHg or diastolic blood pressure persistently \> 110 mmHg). * Coagulation disorders, with a platelet count \< 100×10⁹/L. * Patients with cardiogenic shock. * Patients who need to receive cytostatic agents or radiotherapy due to accompanying diseases. * Patients known to be allergic to heparin, contrast agents, aspirin, clopidogrel, or anesthetics. * Patients with a bleeding diathesis, or those with a history of cerebral hemorrhage, active peptic ulcer, or gastrointestinal bleeding within the past 6 months, for whom anticoagulant therapy or the use of anticoagulant drugs will be restricted or prohibited. * Patients with a life expectancy of less than 6 months or those with potential factors that may cause difficulties in clinical follow-up. * Patients who are currently participating in any other clinical trial. Patients who, for other reasons, are considered by the investigator to be unsuitable for inclusion.